Patient experiences with an online home monitoring program for sarcoidosis

<bold>Introduction:</bold> Sarcoidosis often has a major impact on lives of patients. Online home monitoring (HM) could improve access to care, enhance patient engagement, and enable collection of physiological and patient reported outcomes (PROs). Research on patient experiences with HM is limited in sarcoidosis. We evaluated patient experiences with a HM program. <bold>Methods:</bold> Patients received access to a HM program, as part of a randomized controlled trial (PREDMETH study, <ext-link>NCT04314193</ext-link>). Patients performed weekly home spirometry, reported symptoms, side effects and PROs, and could sent an e-consult via the online HM application (by Curavista). A graphical overview of the data was provided for patients and physicians. Experiences were evaluated via a survey after 24 weeks, including visual analogue scales from 0-10 (negative-positive). <bold>Results:</bold> 92 of the 137 patients completed the survey. Patients reported good usability of the app (median score: 8.5, IQR: 7.4–9.5) and spirometry (8.5, 7.4–9.5). Weekly symptom scoring and spirometry were not burdensome (7.7, 6.2–9.1; 8.6, 7.3–9.4), and patients appreciated physicians’ direct access to their data (9.5, 8.2–10.0). Figure 1 shows more findings. <fig><object-id>erj;66/suppl_69/PA5132/F1</object-id><object-id>F1</object-id><object-id>F1</object-id><graphic></graphic></fig> <bold>Discussion:</bold> Patients with sarcoidosis were generally positive about the online home monitoring program and its usability. Patients valued physicians’ direct access to their data. Integrating HM in research and clinical care holds promise to improve patient-centered care.